Related Experiment Video
Updated: Aug 28, 2025

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Long-Term Withdrawal of Anticoagulation and Antiplatelet Therapy in a HeartMate 3 Left Ventricular Assist Device
Kristina Menchaca1, Catherine A Ostos Perez1, Nemanja Draguljevic2
1Internal Medicine, University of Miami/JFK (John Fitzgerald Kennedy) Medical Center, Atlantis, USA.
Insights
A patient with end-stage heart failure received a HeartMate 3 device. Discontinuing anticoagulation for bleeding did not lead to adverse events like pump thrombosis or thromboembolism.
Area of Science:
- Cardiology
- Medical Devices
- Mechanical Circulatory Support
Background:
- End-stage heart failure necessitates advanced treatment options.
- Left Ventricular Assist Devices (LVADs) improve survival and quality of life.
- HeartMate 3 is an advanced LVAD for advanced heart failure management.
Observation:
- A 73-year-old male with end-stage heart failure received a HeartMate 3 device.
- Systemic anticoagulation and antiplatelet therapy were paused for 52 days due to postoperative bleeding.
- Warfarin monotherapy was reinstituted post-hemorrhage, targeting an INR of 1.8-2.5.
Findings:
- No pump thrombosis was reported eight months post-restart of anticoagulation.
- No thromboembolic events occurred during the follow-up period.
- No significant bleeding events were reported after resuming warfarin therapy.
Implications:
- Temporary cessation of anticoagulation in LVAD patients may be feasible in specific bleeding scenarios.
- Careful management of anticoagulation is crucial for LVAD recipients.
- Further research is needed to establish optimal anticoagulation strategies for LVADs following bleeding complications.
Abstract:
A 73-year-old male with end-stage heart failure underwent insertion of the HeartMate 3 (Abbott, North Chicago, IL, USA) device. Systemic anticoagulation and antiplatelets were discontinued for 52 days due to postoperative bleeding. After hemorrhage resolution, we restarted warfarin monotherapy targeting an international normalized ratio of 1.8-2.5. Eight months later, there are no reports of pump thrombosis, thromboembolism, and bleeding.
Related Concept Videos
Cardiomyopathy V: Interprofessional Care
Cardiac Catheterization III: Left Heart Catheterization
Endocarditis III: Medical Management
Venous Thrombosis III: Interprofessional Care
Myocarditis III: Medical Management
Mitral Stenosis III: Medical Management

